ライフサイエンスコーパス: insulin-like growth factor binding protein

1 There was down-regulation of insulin-like growth factor binding protein 1 (8.4-fold),

2 Low circulating levels of insulin-like growth factor binding protein 1 (IGFBP-1) a

3 Regulation of the liver-restricted insulin-like growth factor binding protein 1 (IGFBP-1) g

4 sulin negatively regulates expression of the insulin-like growth factor binding protein 1 (IGFBP-1) g

5 ntrast, phage-derived peptide antagonists of insulin-like growth factor binding protein 1 (IGFBP-1) h

6 Insulin-like growth factor binding protein 1 (IGFBP-1) i

7 Insulin-like growth factor binding protein 1 (IGFBP-1) i

8 genes and proteins in regenerating liver is insulin-like growth factor binding protein 1 (IGFBP-1),

9 c-containing superoxide dismutase 1 (SOD-1), insulin-like growth factor binding protein 1 (IGFBP-1),

10 a 20-fold increase in hepatic expression of insulin-like growth factor binding protein 1 (IGFBP-1),

11 ession profiling revealed elevated levels of insulin-like growth factor binding protein 1 (IGFBP1) tr

12 (HGF), insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 1 (IGFBP1), m

13 phosphatase [G6Phase], and secreted factors (insulin-like growth factor binding protein 1 [GFBP-1].

14 Insulin-like growth factor binding protein 1 concentrati

15 iferator-activated receptor alpha), IGFBP-1 (insulin-like growth factor binding protein 1), HIF3alpha

16 factor-I, insulin-like growth factor-II, and insulin-like growth factor binding proteins 1, 2, and 3

17 esponse elements located in the promoters of insulin-like growth factor-binding protein 1 (IGFBP1) an

18 anges in microglial secretome and identified insulin-like growth factor-binding protein 1 (IGFBP1) as

19 the insulin-responsive sequence (IRS) in the insulin-like growth factor-binding protein 1 promoter an

20 able to bind to its cognate sites within the insulin-like growth factor-binding protein 1 promoter on

21 articles and chromatin arrays containing the insulin-like growth factor-binding protein 1 promoter.

22 In particular, insulin-like growth factor-binding protein 1 was down-re

23 arboxykinase, tyrosine aminotransferase, and insulin-like growth factor-binding protein 1.

24 ing globulin, estrone, estradiol, C-peptide, insulin-like growth factor-binding proteins 1 and 2, adi

25 ctor receptor-binding protein 10 (GRB10) and insulin-like growth factor-binding proteins 1 and 3 (IGF

26 ttern of the thyroglobulin type 1A domain of insulin-like growth factor-binding proteins 1 and 6.

27 on of multiple genes in the liver, including insulin-like growth factor binding protein-1 (IGFBP-1) a

28 The insulin-like growth factor binding protein-1 (IGFBP-1) g

29 sistance, accompanied by decreased levels of insulin-like growth factor binding protein-1 (IGFBP-1) m

30 The IRSs of the PEPCK and insulin-like growth factor binding protein-1 (IGFBP-1) p

31 patic gene expression using the model of the insulin-like growth factor binding protein-1 (IGFBP-1) p

32 serum insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-1 and -3 (IGF

33 Increased serum levels of insulin-like growth factor binding protein-1 appear to b

34 nts DAF-16 binding to its target site in the insulin-like growth factor binding protein-1 gene, the i

35 We also determined serum insulin-like growth factor binding protein-1 in four add

36 with acute pulmonary embolism had the lowest insulin-like growth factor binding protein-1 level (5 2-

37 Serum insulin-like growth factor binding protein-1 level was m

38 Serum insulin-like growth factor binding protein-1 level was n

39 Serum insulin-like growth factor binding protein-1 levels were

40 Insulin-like growth factor binding protein-1 rose from 5

41 ver-operating-characteristic curve for serum insulin-like growth factor binding protein-1 was 0.98 0.

42 The serum levels of insulin-like growth factor binding protein-1 were higher

43 imately 70% decrease in the plasma levels of insulin-like growth factor binding protein-1, a marker o

44 on protein to activate transcription via the insulin-like growth factor binding protein-1-insulin res

45 0-fold increase in the expression of hepatic insulin-like growth factor binding protein-1.

46 ith available measurements of baseline serum insulin-like growth factor binding protein-1.

47 Insulin-like growth factor-binding protein-1 (IGFBP-1) b

48 cts with an insulin response sequence in the insulin-like growth factor-binding protein-1 (IGFBP-1) g

49 hosphoenolpyruvate carboxykinase (PEPCK) and insulin-like growth factor-binding protein-1 (IGFBP-1) g

50 binds to the insulin response element of the insulin-like growth factor-binding protein-1 (IGFBP-1) p

51 Here, we investigated insulin-like growth factor-binding protein-1 (IGFBP-1),

52 We also show that transcription of insulin-like growth factor-binding protein-1 mRNA, which

53 pG2 hepatoma cells show that FKHR stimulates insulin-like growth factor-binding protein-1 promoter ac

54 ds to enhanced expression of hepatic IGFBP1 (insulin-like growth factor-binding protein-1).

55 roteinase inhibitor and His(140)-Val(141) in insulin-like growth factor-binding protein-1, probably r

56 s PRL, dermal fibroblasts did not co-express insulin-like growth factor-binding protein-1.

57 Our previous studies have shown that insulin-like growth factor binding protein 2 (IGFBP-2) i

58 HLA-DR-degenerate epitope pool derived from insulin-like growth factor binding protein 2 (IGFBP-2).

59 tein 1 (TKA-1); colony stimulating factor-1; insulin-like growth factor binding protein 2 (IGFBP-2);

60 t grades revealed frequent overexpression of insulin-like growth factor binding protein 2 (IGFBP2) in

61 Overexpression of insulin-like growth factor binding protein 2 (IGFBP2) is

62 Insulin-like growth factor binding protein 2 (IGFBP2) is

63 Insulin-like growth factor binding protein 2 (IGFBP2) se

64 oblastomas multiforme) tumors and found that insulin-like growth factor binding protein 2 (IGFBP2) wa

65 There was considerable variability in insulin-like growth factor binding protein 2 concentrati

66 sma macrophage inhibitory protein-1alpha and insulin-like growth factor binding protein 2 showed a si

67 Insulin-like growth factor-binding protein 2 (IGFBP-2) i

68 The levels of insulin-like growth factor-binding protein 2 (IGFBP2) ar

69 Insulin-like growth factor-binding protein 2 (IGFBP2) is

70 e report here, we tested the hypothesis that insulin-like growth factor-binding protein 2 (IGFBP2) pr

71 R), which promotes HIF synthesis, as well as insulin-like growth factor-binding protein 2 (IGFBP2), a

72 everal genes, e.g., Sonic hedgehog (Shh) and Insulin-like growth factor-binding protein 2 (Igfbp2), t

73 xidase 3 (GPX3), apolipoprotein J/clusterin, insulin-like growth factor-binding protein 2, epithelial

74 enin to repress expression of the endogenous insulin-like growth factor binding protein-2 (IGFBP-2) g

75 ide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2) and 5 clin

76 ide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2.

77 s the addition of a neutralizing antibody to insulin-like growth factor-binding protein-2 (IGFBP-2) r

78 increased levels of RNAs encoding p21waf and insulin-like growth factor-binding protein-2.

79 on between prediagnostic levels of IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) a

80 We investigated the expression of insulin-like growth factor binding protein 3 (IGFBP-3) i

81 Insulin-like growth factor binding protein 3 (IGFBP-3) i

82 We hypothesized that loss of insulin-like growth factor binding protein 3 (IGFBP-3) s

83 that insulin-like growth factor 1 (IGF-1) or insulin-like growth factor binding protein 3 (IGFBP-3) w

84 sulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),

85 ons of insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),

86 ular genes, including increased mRNA for the insulin-like growth factor binding protein 3 (IGFBP-3).

87 th factor I (IGF-I) and inversely related to insulin-like growth factor binding protein 3 (IGFBP-3).

88 owth factor binding protein 1 (IGFBP-1), and insulin-like growth factor binding protein 3 (IGFBP-3).

89 growth factor type 1 and its carrier protein insulin-like growth factor binding protein 3 (IGFBP-3).

90 secretome proteomics approach, we identified insulin-like growth factor binding protein 3 (IGFBP3) as

91 or induction of the proapoptotic target gene insulin-like growth factor binding protein 3 (IGFBP3) by

92 K regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), a

93 ugh a previously unappreciated activation of insulin-like growth factor binding protein 3 (IGFBP3), w

94 n binding of insulin-like growth factor-I to insulin-like growth factor binding protein 3 and the pre

95 factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein 3 and these l

96 tion of a specific protease directed against insulin-like growth factor binding protein 3 and to rela

97 Whites had higher 25-hydroxyvitamin D and insulin-like growth factor binding protein 3 but lower 1

98 vity, serum insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrati

99 After 5 days, insulin-like growth factor binding protein 3 concentrati

100 increasing insulin-like growth factor-I and insulin-like growth factor binding protein 3 concentrati

101 Insulin-like growth factor binding protein 3 concentrati

102 of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 in 6,520 wo

103 pression of p53 target genes, p21(waf-1) and insulin-like growth factor binding protein 3 in glioma c

104 onsurvivor, insulin-like growth factor-I and insulin-like growth factor binding protein 3 remained lo

105 trations of insulin-like growth factor-I and insulin-like growth factor binding protein 3 were higher

106 esence of protease activity directed against insulin-like growth factor binding protein 3 were invest

107 a survivor, insulin-like growth factor-I and insulin-like growth factor binding protein 3 were low in

108 S/FLI1 decreased the transcript half-life of insulin-like growth factor binding protein 3, a down-reg

109 tein 7, fibroblast growth factor receptor 2, insulin-like growth factor binding protein 3, and platel

110 the presence of a protease directed against insulin-like growth factor binding protein 3.

111 tease activity specifically directed against insulin-like growth factor binding protein 3.

112 milar inverse associations were observed for insulin-like growth factor binding protein 3.

113 nificant differences by supplement in plasma insulin-like growth factor-binding protein 3 (44 and 40

114 of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) a

115 Insulin-like growth factor-binding protein 3 (IGFBP-3) h

116 Higher levels of insulin-like growth factor-binding protein 3 (IGFBP-3) m

117 d plasminogen activator inhibitor-1 (PAI-1), insulin-like growth factor-binding protein 3 (IGFBP-3),

118 The regulation of insulin-like growth factor-binding protein 3 (IGFBP3) ge

119 for the suppression of HIF-responsive genes insulin-like growth factor-binding protein 3 (IGFBP3), D

120 characterized by down-regulation of Fas and insulin-like growth factor-binding protein 3 and by incr

121 the potential apoptotic targets Bax and the insulin-like growth factor-binding protein 3 gene (IGF-B

122 uences derived from the bax promoter and the insulin-like growth factor-binding protein 3 gene (IGF-B

123 m the p53-responsive portions of the Bax and insulin-like growth factor-binding protein 3 gene promot

124 Insulin-like growth factor-binding protein 3 messenger R

125 messenger RNAs for the IGF-I transgene, and insulin-like growth factor-binding protein 3 were assaye

126 ree thyroxine, insulin-like growth factor 1, insulin-like growth factor-binding protein 3, bone alkal

127 Plasma concentrations of IGF-I, insulin-like growth factor-binding protein 3, serum bone

128 e genes, including glucose transporter-1 and insulin-like growth factor-binding protein 3.

129 cts of insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-3 (IGFBP-3) a

130 n identified neutral endopeptidase (NEP) and insulin-like growth factor binding protein-3 (IGFBP-3) a

131 Insulin-like growth factor binding protein-3 (IGFBP-3) a

132 to determine whether Compound 49b stimulates insulin-like growth factor binding protein-3 (IGFBP-3) a

133 Insulin-like growth factor binding protein-3 (IGFBP-3) c

134 d with IGF-II expression and positively with insulin-like growth factor binding protein-3 (IGFBP-3) e

135 Insulin-like growth factor binding protein-3 (IGFBP-3) h

136 This study proposes a role for insulin-like growth factor binding protein-3 (IGFBP-3) i

137 Insulin-like growth factor binding protein-3 (IGFBP-3) i

138 from this laboratory revealed that vitreous insulin-like growth factor binding protein-3 (IGFBP-3) i

139 to increased endothelial cell expression of insulin-like growth factor binding protein-3 (IGFBP-3) i

140 NKX3.1 expression in PC-3 cells increased insulin-like growth factor binding protein-3 (IGFBP-3) m

141 nd RXR-specific ligands on the regulation of insulin-like growth factor binding protein-3 (IGFBP-3) p

142 Insulin-like growth factor binding protein-3 (IGFBP-3),

143 iTRAQ analysis identified insulin-like growth factor binding protein-3 (IGFBP-3),

144 gulates the well-documented growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3).

145 Here we define insulin-like growth factor binding protein-3 (IGFBP3) as

146 ltered in the Id cKO hearts, but addition of Insulin-Like Growth Factor binding protein-3 (IGFbp3) re

147 Insulin-like growth factor binding protein-3 (IGFBP3) wa

148 asked whether the hypoxia-regulated factor, insulin-like growth factor binding protein-3 (IGFBP3), c

149 insulin-like growth factor-1 (P < 0.03) and insulin-like growth factor binding protein-3 (P < 0.02)

150 ulin-like growth factor-I and restoration of insulin-like growth factor binding protein-3 levels, and

151 ase in plasminogen activator inhibitor-I and insulin-like growth factor binding protein-3 mRNA levels

152 ssion of connective tissue growth factor and insulin-like growth factor binding protein-3 was observe

153 cated in the control of catagen (Bax, Bcl-2, insulin-like growth factor binding protein-3).

154 Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix

155 ng growth regulators (v-sis gene product and insulin-like growth factor binding protein-3, IGFBP-3) a

156 included serum insulin-like growth factor-1, insulin-like growth factor binding protein-3, prolactin,

157 The hepatic expression and serum levels of insulin-like growth factor-binding protein-3 (IGFBP-3) a

158 Insulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-3 (IGFBP-3) a

159 Insulin-like growth factor-binding protein-3 (IGFBP-3) i

160 Insulin-like growth factor-binding protein-3 (IGFBP-3) i

161 er retinoic acid receptor-beta (RARbeta) nor insulin-like growth factor-binding protein-3 (IGFBP-3) i

162 Matrix metalloproteinase 3 cleaves insulin-like growth factor-binding protein-3 (IGFBP-3) i

163 e same cells exhibited dramatic increases in insulin-like growth factor-binding protein-3 (IGFBP-3) m

164 But we found that the expression of insulin-like growth factor-binding protein-3 (IGFBP-3) w

165 Insulin-like growth factor-binding protein-3 (IGFBP-3),

166 identified in patients with ARDS, including insulin-like growth factor-binding protein-3 (IGFBP-3).

167 evels and the induction of wild-type p53 and insulin-like growth factor-binding protein-3 (IGFBP3) 24

168 Insulin-like growth factor-binding protein-3 and -5 (IGF

169 tivates the insulin-response elements of the insulin-like growth factor-binding protein-3 and other i

170 g levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 early in cr

171 ced the anti-proliferative and pro-apoptotic insulin-like growth factor-binding protein-3 expression.

172 mulation (up to 5.8 fold; P < 0.05) of human insulin-like growth factor-binding protein-3 in mouse pl

173 854746 is also significantly associated with insulin-like growth factor-binding protein-3 levels in t

174 ciated with insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 levels; Acu

175 Total insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 were measur

176 Expression of insulin-like growth factor-binding protein-3, which (IGF

177 iability in insulin-like growth factor-1 and insulin-like growth factor-binding protein-3.

178 levels; and age was strongly associated with insulin-like growth factor-binding protein-3.

179 746 was significantly associated with plasma insulin-like growth factor-binding protein-3.

180 Insulin-like growth factor binding protein 4 (IGFBP4/BP4

181 nocerebellar ataxia [SCA1]), growth factors (insulin-like growth factor binding protein 4 and transfo

182 The insulin-like growth factor-binding protein 4 (IGFBP-4),

183 The insulin-like growth factor-binding protein 4 (IGFBP-4),

184 ced level of metastasis-suppressive protein, insulin-like growth factor-binding protein 4.

185 To identify the molecular mechanism by which insulin-like growth factor binding protein-4 (IGFBP-4) e

186 lagen type IV may suppress the expression of insulin-like growth factor binding protein-4 (IGFBP-4),

187 Furthermore, the differential expression of insulin-like growth factor binding protein 5 (IGFBP-5) w

188 Since C1s degrades insulin-like growth factor binding protein 5 (IGFBP-5),

189 scriptional changes, with down-regulation of insulin-like growth factor binding protein 5 (Igfbp5) re

190 Three genes (lumican, biglycan, and insulin-like growth factor binding protein 5) encoded ex

191 tor, laminin receptor homolog, beta-tubulin, insulin-like growth factor binding protein 5, KIAA0179 p

192 Expression of the insulin-like growth factor-binding protein 5 (IGFBP-5) g

193 Insulin-like growth factor-binding protein 5 (IGFBP-5) i

194 d a strong upregulation in the expression of insulin-like growth factor-binding protein 5 (IGFBP5), a

195 eracts with the promoter of IGFBP5 (encoding insulin-like growth factor-binding protein 5) and displa

196 sformed BT549 cells include C-type lectin 2, insulin-like growth factor-binding protein 5, cathepsins

197 ins had an alteration in their expression of insulin-like growth factor binding protein-5 (IGFBP-5) a

198 The authors found transcript expression for insulin-like growth factor binding protein-5 (IGFBP-5) w

199 retinal glia and appeared to be mediated by insulin-like growth factor binding protein-5 (IGFBP-5),

200 crete an 88-kDa serine protease that cleaves insulin-like growth factor binding protein-5 (IGFBP-5).

201 Insulin-like growth factor binding protein-5, the homeob

202 Insulin-like growth factor-binding protein-5 (IGFBP-5) a

203 Insulin-like growth factor-binding protein-5 (IGFBP-5) h

204 Insulin-like growth factor-binding protein-5 (IGFBP-5) h

205 Insulin-like growth factor-binding protein-5 (IGFBP-5) i

206 Insulin-like growth factor-binding protein-5 (IGFBP-5) i

207 Glucocorticoids inhibit the synthesis of insulin-like growth factor-binding protein-5 (IGFBP-5) i

208 gly Akt induced significant up-regulation of insulin-like growth factor-binding protein-5 (IGFBP-5),

209 cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5).

210 nd up-regulation of one of its target genes, insulin-like growth factor-binding protein-5, which is t

211 pression of CITED1, claudin-10 (CLDN10), and insulin-like growth factor binding protein 6 (IGFBP6) bu

212 owth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta,

213 to the inflammation-associated transcripts, insulin-like growth factor-binding protein 6, macrophage

214 PAOh1 and ELF3, while prominent induction of insulin-like growth-factor-binding protein 6 (IGFBP6) st

215 -1, cartilage oligomeric matrix protein, and insulin-like growth factor binding protein 7 concentrati

216 Cartilage oligomeric matrix protein, insulin-like growth factor binding protein 7, and beta-g

217 transcripts, including the tumor suppressor insulin-like growth factor binding protein 7.

218 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 accurately

219 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients

220 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in this pop

221 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 results in

222 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 significant

223 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 test was no

224 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was 0.84 (0

225 owed by a marker of cell cycle arrest (urine insulin-like growth factor-binding protein 7) and, final

226 onal induction of the Drosophila ortholog of insulin-like growth factor-binding protein 7, which syst

227 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7.

228 or-suppressor gene (period homolog 3 [PER3], insulin-like growth-factor-binding protein, acid labile

229 alog of IGF-I with very low affinity for the insulin-like growth factor-binding proteins (IGF-BPs), d

230 The insulin-like growth factor binding protein IGFBP-3 is a

231 insulin and depressed levels of circulating insulin-like growth factor binding protein (IGFBP) -1, w

232 oth RA and TGF-beta2 increased the levels of insulin-like growth factor binding protein (IGFBP) 3 (2-

233 valuated the relationship of insulin, IGF-I, insulin-like growth factor binding protein (IGFBP) 3, an

234 , as expected if Notch1 loss altered the IGF/insulin-like growth factor binding protein (IGFBP) balan

235 nhibits prostate cancer growth and increases insulin-like growth factor binding protein (IGFBP) expre

236 ing indicated substantial down-regulation of insulin-like growth factor binding protein (Igfbp) genes

237 f the fetal insulin-like growth factor (IGF)-insulin-like growth factor binding protein (IGFBP) syste

238 To determine the cellular source of this insulin-like growth factor binding protein (IGFBP), 11 m

239 traction-promoting activity, the presence of insulin-like growth factor binding protein (IGFBP), and

240 Insulin-like growth factor binding protein (IGFBP)-1 has

241 Insulin-like growth factor binding protein (IGFBP)-1 inf

242 es and insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein (IGFBP)-1, an

243 tor (PDGF) isoforms (PDGF-AA, -BB, and -AB), insulin-like growth factor binding protein (IGFBP)-2, an

244 Insulin-like growth factor binding protein (IGFBP)-3 reg

245 Insulin-like growth factor binding protein (IGFBP)-5 is

246 Insulin-like growth factor binding protein (IGFBP)-5 is

247 , we examined the expression and function of insulin-like growth factor binding proteins (IGFBP)-3 an

248 d hepatocyte nuclear factor (HNF) 4alpha and insulin-like growth factor-binding protein (IGFBP) 1 mRN

249 CCN1 comprising completely or partially the insulin-like growth factor-binding protein (IGFBP) and v

250 quadricarinatus, we have identified a novel insulin-like growth factor-binding protein (IGFBP) terme

251 Insulin-like growth factor-binding protein (IGFBP)-1 bin

252 Previous studies have shown that insulin-like growth factor-binding protein (IGFBP)-2 is

253 experiments demonstrated that PAPP-A cleaves insulin-like growth factor-binding protein (IGFBP)-2, bu

254 med gene expression profiling and identified insulin-like growth factor-binding protein (IGFBP)-3 as

255 Insulin-like growth factor-binding protein (IGFBP)-3 has

256 Insulin-like growth factor-binding protein (IGFBP)-3 is

257 Insulin-like growth factor-binding protein (IGFBP)-3 reg

258 Insulin-like growth factor-binding protein (IGFBP)-3, we

259 Binding of STC2 prevents PAPP-A cleavage of insulin-like growth factor-binding protein (IGFBP)-4 and

260 Insulin-like growth factor-binding protein (IGFBP)-5 is

261 We have recently shown that insulin-like growth factor-binding protein (IGFBP)-5 is

262 We found increased levels of secreted insulin-like growth factor-binding proteins (IGFBP) in t

263 ortic smooth muscle cells (SMCs) secrete two insulin-like growth factor-binding proteins (IGFBP), IGF

264 ts of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP).

265 High affinity insulin-like growth factor-binding proteins (IGFBP-1 to

266 In this setting, the insulin-like growth factor binding protein IGFBP7 inhibi

267 early response (TIEG), SMAD5, SMAD7, SMAD2, insulin-like growth factor binding protein (IGFBP7), IGF

268 was associated with a marked upregulation of insulin-like growth factor binding proteins (IGFBPs) 3 a

269 igment epithelial (RPE) cells as a source of insulin-like growth factor binding proteins (IGFBPs) and

270 Insulin-like growth factor binding proteins (IGFBPs) are

271 The insulin-like growth factor binding proteins (IGFBPs) are

272 Proteolytic cleavage of the six known insulin-like growth factor binding proteins (IGFBPs) is

273 ase have been associated with changes in the insulin-like growth factor binding proteins (IGFBPs), a

274 gulated by six soluble binding proteins, the insulin-like growth factor binding proteins (IGFBPs), wh

275 ity are, in part, attributable to changes in insulin-like growth factor binding proteins (IGFBPs).

276 The effects of IGFs are modulated by insulin-like growth factor binding proteins (IGFBPs).

277 ine if ERT in vivo affects the production of insulin-like growth factor binding proteins (IGFBPs).

278 The extracellular insulin-like growth factor-binding proteins (IGFBPs) are

279 The six high-affinity insulin-like growth factor-binding proteins (IGFBPs) com

280 Insulin-like growth factors (IGFs) and insulin-like growth factor-binding proteins (IGFBPs) pla

281 generation and the contributions of vitreous insulin-like growth factor-binding proteins (IGFBPs) tow

282 as to evaluate the contributions of vitreous insulin-like growth factor-binding proteins (IGFBPs) tow

283 acellular matrix (ECM) contains two forms of insulin-like growth factor-binding proteins (IGFBPs), IG

284 propeptide shares a 20-25% identity to human insulin-like growth factor-binding proteins (IGFBPs), su

285 atocyte growth factor, endocrine gland VEGF, insulin-like growth factor binding proteins, or endostat

286 Increased expression of mac25/insulin-like growth factor binding-protein related prote

287 Insulin-like growth factor binding protein-related prote

288 25.1, a novel protein interacting with mac25/insulin-like growth factor-binding protein-related prote

289 on their apical surface, and the profile of insulin-like growth factor binding proteins resembled th

290 mains that bear sequence similarities to the insulin-like growth factor-binding proteins, von Willebr